Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year...( RANCHO CORDOVA Calif. March 2 /- Ther...),Health

RANCHO CORDOVA, Calif., March 2 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading developer and supplier of products that process and store adult stem cells, announced today that products derived from its Intellectual Property have been used to collect, process and store stem cells from cord blood in more than one million procedures since the products were introduced a decade ago. Cord blood stem cells have been used to reconstitute the blood cell forming marrow of patients undergoing treatment for leukemia and lymphoma. Cord blood is also being used in studies regarding treatment for more than 70 genetic diseases and most recently, cerebral palsy.

"The collection and processing of stem cells from cord blood utilizing these products has increased dramatically over the past decade, rising from 5,000 units in 1999 to more than 250,000 units in 2008," said Matthew Plavan, Chief Executive Officer of ThermoGenesis Corp.

These products include:

• Sterile disposable bag sets used to collect cord blood from the placenta/umbilical cord and other manual disposable bag sets that concentrate the stem cells resident in the cord blood.
• Novel sterile disposable bag sets that take advantage of the AutoXpress(TM) Platform to harvest and concentrate stem cells through automated means.

"We believe that the ongoing research regarding the therapeutic benefits of stem cells and the likely expansion of financial support for stem cell programs will mandate greater activity in the collection, processing, freezing and storage of cord blood stem cell units in the future," Plavan said.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.the
'/>"/>